BJU International最新文献_第4页

The LANDMARK project: providing summaries of key papers that have shaped urological practice. LANDMARK 项目：提供影响泌尿外科实践的重要论文摘要。

IF 3.7 2区医学

BJU International Pub Date : 2024-10-09 DOI: 10.1111/bju.16548

Kevin G Byrnes, Cameron Alexander, Mariam Lami, Marie Edison, Aqua Asif, Alexander Ng, Quentin Mak, Bing Jie Chow, Mathew Smith, Kevin Keane, Kevin Gallagher, Arjun S Nathan, Sinan Khadhouri, Nikita R Bhatt, Veeru Kasivisvanathan

引用次数: 0

Ureteric stenting outside of the operation theatre: challenges and opportunities. 手术室外的输尿管支架植入术：挑战与机遇。

IF 3.7 2区医学

BJU International Pub Date : 2024-10-08 DOI: 10.1111/bju.16533

Patrick Gordon, Daryl Thompson, Oneel Patel, Ronald Ma, Damien Bolton, Joseph Ischia

{"title":"Ureteric stenting outside of the operation theatre: challenges and opportunities.","authors":"Patrick Gordon, Daryl Thompson, Oneel Patel, Ronald Ma, Damien Bolton, Joseph Ischia","doi":"10.1111/bju.16533","DOIUrl":"https://doi.org/10.1111/bju.16533","url":null,"abstract":"Objective: To evaluate the safety, efficacy, tolerability, and cost-effectiveness of bedside or office-based ureteric stent insertion.Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-P) and A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 guidelines, we searched PubMed/the Medical Literature Analysis and Retrieval System Online (MEDLINE), the Excerpta Medica dataBASE (EMBASE), Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL), and Dimensions for English-language studies from 1978 to April 2023. Inclusion criteria focused on primary ureteric stent placements outside of the operating theatre (OT).Results: A total of 15 studies involving 2072 stents were included. Success rates for correctly positioned stents in bedside or office-based insertions ranged from 60% to 95.8%, with most studies reporting ≥80% success rates. Common failure reasons included impacted stones and difficulty identifying the ureteric orifice. Pain and tolerability were assessed using various methods, with validated tools indicating moderate pain levels, but most patients would undergo the procedure again under local anaesthesia. Complication rates were generally low, with minor complications such as haematuria or postoperative fever being the most common. Procedural costs were significantly lower in non-OT settings, with estimates indicating savings of up to four-fold.Conclusion: Bedside or office-based ureteric stent insertion is a viable alternative to OT procedures, offering high success rates, manageable pain levels, low complication rates, and substantial cost savings. This approach is particularly advantageous in settings with limited OT access, highlighting its potential for broader adoption in urological practice. Future research should focus on standardising pain assessment methods and randomised studies.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bladder-centric benign prostatic hyperplasia management post-laser enucleation of the prostate. 前列腺激光去核术后以膀胱为中心的良性前列腺增生症治疗。

IF 3.7 2区医学

BJU International Pub Date : 2024-10-08 DOI: 10.1111/bju.16544

Yu-Hsiang Lin, Chih-Te Lin, Kuo-Jen Lin

引用次数: 0

Response to letter 'Bladder-centric benign prostatic hyperplasia management post-laser enucleation of the prostate'. 对 "激光前列腺去核术后以膀胱为中心的良性前列腺增生管理 "一信的回复。

IF 3.7 2区医学

BJU International Pub Date : 2024-10-08 DOI: 10.1111/bju.16542

Cristina Cano Garcia, Andreas Becker

引用次数: 0

Single-port robot-assisted nephroureterectomy via a supine anterior approach: step-by-step technique. 通过仰卧前路进行的单孔机器人辅助肾切除术：循序渐进的技术。

IF 3.7 2区医学

BJU International Pub Date : 2024-10-03 DOI: 10.1111/bju.16537

Alessandro Izzo, Gianluca Spena, Giovanni Grimaldi, Giuseppe Quarto, Luigi Castaldo, Raffaele Muscariello, Dario Franzese, Francesco Passaro, Riccardo Autorino, Antonio Tufano, Sisto Perdonà

引用次数: 0

The 'balls' of an ideal man? 理想男人的 "蛋蛋"？

IF 3.7 2区医学

BJU International Pub Date : 2024-10-03 DOI: 10.1111/bju.16538

Farrokh Habibzadeh

引用次数: 0

Residual cancer at radical cystectomy with or without neoadjuvant chemotherapy: a pathological stage‐matched comparison 根治性膀胱切除术后残留癌与新辅助化疗的比较：病理分期比较

IF 4.5 2区医学

BJU International Pub Date : 2024-10-02 DOI: 10.1111/bju.16529

Leilei Xia, J. Everett Knudsen, Daniel S. Roberson, Erika L. Wood, Anosh Dadabhoy, Sofia Romano, Thomas J. Guzzo, Trinity J. Bivalacqua, Siamak Daneshmand

引用次数: 0

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. 高风险非肌层浸润性膀胱癌的实际疗效：BRAVO 试验筛选出的患者。

IF 4.5 2区医学

BJU International Pub Date : 2024-09-26 DOI: 10.1111/bju.16516

Samantha Conroy,Ibrahim Jubber,Aidan P Noon,Derek J Rosario,Jon Griffin,Susan Morgan,Rachel Hubbard,Steve Kennish,Stephen Mitchell,Suresh Venugopal,Kate Linton,Ramanan Rajasundaram,Syed A Hussain,James W F Catto

{"title":"Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial.","authors":"Samantha Conroy,Ibrahim Jubber,Aidan P Noon,Derek J Rosario,Jon Griffin,Susan Morgan,Rachel Hubbard,Steve Kennish,Stephen Mitchell,Suresh Venugopal,Kate Linton,Ramanan Rajasundaram,Syed A Hussain,James W F Catto","doi":"10.1111/bju.16516","DOIUrl":"https://doi.org/10.1111/bju.16516","url":null,"abstract":"OBJECTIVETo report real-world outcomes for high-risk non-muscle-invasive bladder cancer (HRNMIBC), including bacillus Calmette-Guérin (BCG) and radical cystectomy (RC), as randomised comparisons of these have not been possible.METHODSWe detail consecutive participants screened for the BRAVO randomised controlled trial comparing RC with BCG (International Standard Randomised Controlled Trial Number [ISRCTN]12509361). Patients were prospectively registered and case-note review used for outcomes. The primary outcome was overall survival. Secondary outcomes included recurrence, progression, metastasis, and bladder cancer-specific survival.RESULTS AND LIMITATIONSA total of 193 patients were screened, including 106 (54.9%) who received BCG, 43 (22.3%) primary RC, 37 (19.2%) 'other' treatment and seven (3.6%) hyperthermic intravesical mitomycin C. All-cause death occurred in 55 (28.5%) patients at median (interquartile range [IQR]) of 29.0 (19.5-42.0) months. In multivariable analysis, overall mortality was more common in older patients (hazard ratio [HR] 2.63, 95% confidence interval [CI] 1.35-5.13; Cox P = 0.004 for age >70 years), those recruited from district hospitals (HR 0.53, 95% CI 0.3-0.95; P = 0.032) and those who did not undergo RC as their first treatment (HR 2.16, 95% CI 1.17-3.99; P = 0.014). In all, 17 (8.8%) patients died from bladder cancer (BC) at median (IQR) of 22.5 (19-36.25) months. In multivariable analysis, BC-specific mortality was more common in older patients (HR 4.87, 95% CI 1.1-21.6; P = 0.037) and those with Tis/T1 disease (HR 2.26, 95% CI 1.23-4.16; P = 0.008) but did not vary with initial treatment.CONCLUSIONSPatients with HRNMIBC are at high-risk of mortality. Those choosing RC as their initial treatment have lower risks of mortality than others, although this may reflect fitness and selection.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

October's reviewers of the month 十月份的月度评论员

IF 3.7 2区医学

BJU International Pub Date : 2024-09-24 DOI: 10.1111/bju.16524

引用次数: 0

The use of 99mTc‐tetrofosmin in the characterisation of indeterminate renal masses: a pilot study 使用 99mTc-tetrofosmin 对不确定的肾肿块进行定性：一项试点研究

IF 4.5 2区医学

BJU International Pub Date : 2024-09-23 DOI: 10.1111/bju.16507

Ergi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, Sara Sheikhbahaei, Krystyna M. Jones, Mehrbod S. Javadi, Basil Kaufmann, Mohamad E. Allaf, Christian P. Pavlovich, Nirmish Singla, Lilja B. Solnes, Michael A. Gorin, Steven P. Rowe

引用次数: 0